ArticleMolecular biology reports2026
β-caryophyllene protects against foodborne ochratoxin A-induced pancreatic toxicity: implications for food safety and environmental health.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ochratoxin A (OTA) is a pervasive foodborne mycotoxin linked to multisystem toxicity, including pancreatic toxicity. Increasing evidence indicates that oxidative stress and inflammation caused by OTA are pivotal behind pancreatic damage. β-Caryophyllene (BCP), a natural sesquiterpene found in consumable flora, demonstrates significant antioxidant and anti-inflammatory effects. The objective of this study was to examine the protective effect of BCP against OTA-induced pancreatic toxicity, focusing on the modulation of the Nrf2/HO-1 and NQO1 antioxidant pathway and the NF-κB-mediated activation of the NLRP3 inflammasome. Experimental animals were subjected to OTA to elicit pancreatic toxicity and simultaneously administered BCP at both low and high dosages. OTA exposure caused significant pancreatic damage, as indicated by increased oxidative stress, activation of NF-κB and NLRP3 inflammasome signaling, and notable histoarchitectural disruption. BCP therapy markedly reduced OTA-induced pancreatic damage in a dose-dependent manner. BCP augmented intrinsic antioxidant defenses through the activation of the Nrf2/HO-1 and NQO1 pathway, while simultaneously inhibiting NF-κB activation and subsequent NLRP3 inflammasome signaling. BCP significantly alleviates OTA-induced pancreatic damage by reestablishing redox equilibrium, suppressing inflammatory signaling pathways and normalizing the pathological changes. These findings offer new understanding of the molecular mechanisms behind OTA-induced pancreatic damage, and highlight BCP as a potential dietary strategy for mitigating mycotoxin-related pancreatic impairment.
Indexed as
Identifiers
42171838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.